Gsk (GLAXF) Total Non-Current Liabilities (2009 - 2026)

Gsk's Total Non-Current Liabilities history runs 18 years deep, the most recent figure standing at -$31.0 billion for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 6.03% year-over-year to -$31.0 billion; the TTM figure through Mar 2026 stood at -$31.0 billion (up 6.03% YoY), while the FY2025 annual figure was -$31.3 billion, down 199.35% from the prior year.
• Total Non-Current Liabilities was -$31.0 billion for Q1 2026 at Gsk, up from -$31.6 billion in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $32.0 billion in Q4 2022 to a low of -$36.1 billion in Q3 2022.
• Historically, Total Non-Current Liabilities has averaged -$20.3 billion across 5 years, with a median of -$31.6 billion in 2025.
• The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities jumped 65.23% in 2022, then sank 199.82% in 2025.
• A 5-year view of Total Non-Current Liabilities shows it stood at $32.0 billion in 2022, then dropped by 2.33% to $31.2 billion in 2023, then advanced by 1.51% to $31.7 billion in 2024, then slumped by 199.82% to -$31.6 billion in 2025, then advanced by 1.86% to -$31.0 billion in 2026.
• The last three Total Non-Current Liabilities figures came in at -$31.0 billion (Q1 2026), -$31.6 billion (Q4 2025), and -$32.7 billion (Q3 2025), per Business Quant data.